In Parkinson’s disease, bilateral putaminal infusions of a high or low dose of AAV2-aromatic L-amino acid decarboxylase (AADC) could last at least 4 years, sustaining the expression of AADC, which supports the therapeutic effect of AAV delivery for a few years [49]. Here, DDC is linked to Parkinson disease.